News

From the ALFA group

The new institute Carnot OPALE unites French partnership research on leukemia

10/01/2020

The newly created institute Carnot OPALE gathers the most important research and development French teams working in the field of leukemia and related disorders. This makes OPALE the reference partner for all companies developing innovate diagnostic, therapeutic and follow-up tools for patients with these diseases.

Leukemias and related disorders are the more devastating blood cancers. Their incidence is increasing, with 2.3 million people currently suffering from these diseases. They also represent the most frequent childhood cancers.

The institute Carnot OPALE (Organization for Partnership Research in Leukemia) structures all the preclinical and clinical French research forces, with the aim to present a comprehensive R&D offer to industrial companies interested in this medical field. OPALE belongs to the 39 institutes Carnot labeled in February 2020 by the French Ministry for Higher Education, Research and Innovation for a 4-year period of time.

The institute, member of the Institute Carnot Association and the FINDMED consortium, a research partner for medicinal product SME, gathers 17 research teams, 7 cooperative groups and 4 R&D platforms,1 covering the entire R&D chain as well as the medical and industrial valorization processes.

Basic, translational and clinical research fields of OPALE include:
• New therapeutic target discovery
• Innovative drug development, including cell and gene therapies
• Hospital diagnosis and care
• Clinical trials
• Real-world and long-term follow-up
• Startup incubation

With approximately 700 full-time equivalent employees and an annual 7.2 M€ budget of partnership research, the ultimate goal of OPALE is to define new curative, ambulatory, less toxic and financially sustainable treatment options for all patients with leukemia and related disorders during the next 10-year period.
Website: https://www.opale.org


OPALE entities:

- Cooperative groups for clinical research:
• The Organization for Partnerships in Leukemia (OPALE)
• Acute Leukemia French Association (ALFA),
• Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),
• French Innovative Leukemia Organization, (FILO),
• Groupe Francophone des Myélodysplasies (GFM),
• French Intergroup Myeloproliferative Disorders (FIM),
• Société Française de Lutte contre les Cancers et Leucémies de l’Enfant et de l'Adolescent (SFCE),

- Research teams:
• Centre National de Médecine de Précision sur les Leucémies THEMA (UMR-944, UMR-1131, UMR-1160, UMR-976, EA-3518, Institut de Recherche Saint-Louis, Université de Paris),
• Centre de Recherche en Cancérologie de Marseille (UMR-1068 ; Institut Paoli-Calmettes, Université Aix-Marseille),
• Centre de Recherche en Cancérologie de Toulouse (UMR-1037 ; Oncopôle, Université de Toulouse III),
• Université de Bourgogne Franche-Comté (UMR-1098 ; Besançon),
• Institut de Radiobiologie Cellulaire et Moléculaire (UMR-1274, CEA Fontenay-aux-Roses),
• Institut IDMIT (UMR-1184 ; CEA Fontenay-aux-Roses),
• Institut Cochin (UMR-1016 ; Université de Paris),
• Gustave Roussy (UMR-1170 ; Université Paris Saclay)
• Centre de Recherche Saint-Antoine (UMR-938 ; Sorbonne Université),
• Centre de Recherche Jean-Pierre Aubert (UMR-1172 ; Université de Lille),
• Centre Méditérranéen de Médecine Moléculaire (INSERM-1065 ; Université Nice Cote d’Azur),
• Université de Bordeaux (UMR-1035),
• Université de Tours (ERL7501 LNOX),

- R&D platforms:
• Plateforme Meary de Thérapie Cellulaire et Génique / CIC-BT (Paris Saint-Louis),
• Plateforme de Thérapie Cellulaire et Génique / CIC-BT (Marseille IPC),
• Plateforme Meary de R&D Génomique et Bioinformatique (Paris Saint-Louis),
• Plateforme MI-mAbs Antibodies for Medicine (Marseille)


Contacts:
Hervé Dombret, M.D./ Professor of Hematology, Institut de Recherche Saint-Louis, Hôpital Saint-Louis (AP-HP), OPALE Chairman

Pascal Deschaseaux, M.D./ OPALE General Director / pascal.deschaseaux@opale.org

See the video